FDA

News

Merck wins FDA nod for Keytruda as adjuvant kidney cancer tr...

Merck & Co has chalked up another win in drive to move PD-1 inhibitor Keytruda earlier in the treatment pathway for cancer, after the FDA greenlit use of the drug as post-surgery (adjuv

News

Biden confirms Califf choice as FDA commissioner

President Joe Biden ended months of speculation by formally nominating Robert Califf as the new commissioner of the FDA, a position he previously held during the Obama administration.

News

Novartis' 'wild card' drug Scemblix gets FDA nod for leukaem...

Novartis has claimed FDA approval for one of its 'wild card' drugs – Scemblix – a first-in-class STAMP inhibitor for patients with previously-treated chronic myeloid leukaemia (CML).

News

AbbVie claims first FDA okay for presbyopia drug therapy

The FDA has approved the first and so far only pharmacological treatment for presbyopia, a sight condition that typically starts in middle age and involves difficulty in focusing on near ob

News

Lilly files Alzheimer's drug donanemab as Cortexyme rival fa...

Eli Lilly has followed through on its plan to file for approval of its Alzheimer's disease candidate donanemab, and is planning to take on Biogen and Eisai with a head-to-head trial against

News

Biogen, Sage prep 2022 filing for depression drug zuranolone

The renaissance of Biogen and Sage Therapeutics antidepressant zuranolone continues, with the companies indicating they now plan to start a rolling submission for the drug early next year.<

Merck wins FDA nod for Keytruda as adjuvant kidney cancer tr...

Biden confirms Califf choice as FDA commissioner

Novartis' 'wild card' drug Scemblix gets FDA nod for leukaem...

AbbVie claims first FDA okay for presbyopia drug therapy

Lilly files Alzheimer's drug donanemab as Cortexyme rival fa...

Biogen, Sage prep 2022 filing for depression drug zuranolone

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

FDA

Editor's Picks